Deal Library / Pharma BD Deal Intelligence

Genentech, Inc. (Roche Group) — Pharma Deals

The Pharma Closeout tracks 9 deals, $12.0B in disclosed deal value, 4 with a post-close Outcome Score for Genentech, Inc. (Roche Group).

Median Critic Score: 92  ·  Median Outcome Score: 90

Best outcome: Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. (100)  ·  Weakest outcome: Genentech, Inc. (Roche Group) / Astex Pharmaceuticals (58)

All 9 deals

• Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. — 2026 · $1.0B · Worked — the deal delivered on its rationale.
• Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. — 2026 · $2.3B · Worked — the deal delivered on its rationale.
• Genentech, Inc. (Roche Group) / Tanox Inc. — 2006 · $919M · Worked — the deal delivered on its rationale.
• Genentech, Inc. (Roche Group) / Astex Pharmaceuticals — 2026 · $490M · Mixed — partial payoff, real shortfalls.
• Genentech, Inc. (Roche Group) / MaxCyte, Inc. — 2026
• Genentech, Inc. (Roche Group) / OMass Therapeutics Ltd. — 2025 · $420M
• Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. — 2024 · $850M
• Genentech, Inc. (Roche Group) / Affimed N.V. — 2018 · $5.1B
• Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. — 2016 · $910M

← Deal Library  ·  Interactive search  ·  How we score deals